Vanguard Fiduciary Trust
ASBP

Vanguard Fiduciary Trust’s Aspire Biopharma ASBP Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.8K Buy
10,081
+9,986
+10,512% +$102K ﹤0.01% 3851
2026
Q1 		$2.94K Buy
+95
New +$5.06K ﹤0.01% 4045

Other funds holding ASBP

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Vanguard Fiduciary Trust's ASBP Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Aspire Biopharma (ASBP) stake by 10,512% in Q2 2026, buying an estimated $102K and bringing the position to 10,081 shares worth $53.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3851.

Vanguard Fiduciary Trust first reported a position in ASBP in Q1 2026 and has held it in 2 quarters since. 14 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

  • Vanguard Fiduciary Trust held 10,081 shares of Aspire Biopharma worth $53.8K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 9,986 Aspire Biopharma shares in Q2 2026, an estimated $102K.
  • Aspire Biopharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3851 holding.
  • Vanguard Fiduciary Trust first reported a position in Aspire Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 14 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.